Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 1
2000 1
2008 2
2010 1
2012 1
2013 2
2014 2
2015 13
2016 14
2017 38
2018 29
2019 24
2020 14
2021 11
2022 14
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 29884162

146 results

Results by year

Filters applied: . Clear all
Page 1
Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
Yamauchi I, Sakane Y, Fukuda Y, Fujii T, Taura D, Hirata M, Hirota K, Ueda Y, Kanai Y, Yamashita Y, Kondo E, Sone M, Yasoda A, Inagaki N. Yamauchi I, et al. Thyroid. 2017 Jul;27(7):894-901. doi: 10.1089/thy.2016.0562. Epub 2017 Jun 21. Thyroid. 2017. PMID: 28537531
Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab.
Yamauchi I, Yasoda A, Matsumoto S, Sakamori Y, Kim YH, Nomura M, Otsuka A, Yamasaki T, Saito R, Kitamura M, Kitawaki T, Hishizawa M, Kawaguchi-Sakita N, Fujii T, Taura D, Sone M, Inagaki N. Yamauchi I, et al. PLoS One. 2019 May 14;14(5):e0216954. doi: 10.1371/journal.pone.0216954. eCollection 2019. PLoS One. 2019. PMID: 31086392 Free PMC article.
Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab.
Fujisawa Y, Yoshino K, Otsuka A, Funakoshi T, Fujimura T, Yamamoto Y, Hata H, Gosho M, Tanaka R, Yamaguchi K, Nonomura Y, Hirai I, Furudate S, Okuhira H, Imafuku K, Aoki M, Matsushita S. Fujisawa Y, et al. J Dermatol Sci. 2017 Nov;88(2):225-231. doi: 10.1016/j.jdermsci.2017.07.007. Epub 2017 Jul 16. J Dermatol Sci. 2017. PMID: 28736218
Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.
Toi Y, Sugawara S, Kawashima Y, Aiba T, Kawana S, Saito R, Tsurumi K, Suzuki K, Shimizu H, Sugisaka J, Ono H, Domeki Y, Terayama K, Nakamura A, Yamanda S, Kimura Y, Honda Y. Toi Y, et al. Oncologist. 2018 Nov;23(11):1358-1365. doi: 10.1634/theoncologist.2017-0384. Epub 2018 Jun 22. Oncologist. 2018. PMID: 29934411 Free PMC article.
Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients.
Fujisawa Y, Yoshino K, Otsuka A, Funakoshi T, Uchi H, Fujimura T, Matsushita S, Hata H, Okuhira H, Tanaka R, Nagai K, Ishida Y, Nakamura Y, Furudate S, Yamamura K, Imafuku K, Yamamoto Y. Fujisawa Y, et al. J Dermatol Sci. 2018 Jan;89(1):60-66. doi: 10.1016/j.jdermsci.2017.10.009. Epub 2017 Oct 25. J Dermatol Sci. 2018. PMID: 29079332
146 results